{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:39:07Z","timestamp":1776407947226,"version":"3.51.2"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"CRUK","doi-asserted-by":"publisher","award":["C157\/A25193"],"award-info":[{"award-number":["C157\/A25193"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"Abstract<\/jats:title>\n \n STUDY QUESTION<\/jats:title>\n Do the Edinburgh Selection Criteria correctly identify female cancer patients under the age of 18 who are at risk of premature ovarian insufficiency (POI) as candidates for ovarian tissue cryopreservation (OTC)?<\/jats:p>\n <\/jats:sec>\n \n SUMMARY ANSWER<\/jats:title>\n Patient assessment using these criteria accurately identifies those at risk of POI, who can be offered OTC and future transplantation as a means of fertility preservation.<\/jats:p>\n <\/jats:sec>\n \n WHAT IS KNOWN ALREADY<\/jats:title>\n Treatment for childhood cancer can have adverse consequences on future fertility; at the time of diagnosis, fertility risk assessment should be undertaken in order to identify patients to whom fertility preservation should be offered. The Edinburgh selection criteria, based on planned cancer treatment and patient health status, are utilized to identify those at high risk and therefore eligible for OTC. However, this procedure is not without risk and there are few data on the efficacy of the procedure in prepubertal patients. As such, long-term follow-up of reproductive outcomes is necessary, to ensure that OTC is being offered appropriately.<\/jats:p>\n <\/jats:sec>\n \n STUDY DESIGN, SIZE, DURATION<\/jats:title>\n Cohort study encompassing all females diagnosed with cancer under the age of 18 in South East Scotland, from 1 January 1996 to 30 April 2020. Patients were followed up for reproductive outcomes to assess for diagnosis of POI.<\/jats:p>\n <\/jats:sec>\n \n PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n A total of 638 eligible patients were identified; patients under the age of 12 or deceased before the age of 12 were excluded from the study, leaving a study population of 431 patients. Electronic records were reviewed for reproductive function, assessed by current menstruation, pregnancy (in the absence of POI diagnosis), reproductive hormone measurements, pubertal progression, or diagnosis of POI. Patients on hormonal contraception (other than for treatment of POI or panhypopituitarism with no history of gonadatoxic treatment) were excluded from analysis (n\u2009=\u20099). Analysis on remaining 422 patients was carried out using the Kaplan\u2013Meier methods, with POI as the defined event, and Cox proportional hazards model.<\/jats:p>\n <\/jats:sec>\n \n MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n In the study population of 431 patients, median ages at diagnosis and analysis were 9.8 and 22.2\u2009years, respectively. Reproductive outcomes were unavailable in 142 patients; the assumption was made that these patients did not have POI, but a subanalysis excluding these patients was also performed. Of the 422 patients aged &gt;12 at analysis and not taking hormonal contraception, OTC was offered to 37 patients and successfully performed in 25 patients. Of the 37 patients offered OTC (one at time of relapse), nine (24.3%) developed POI. Of the 386 not offered OTC, 11 (2.9%) developed POI. The probability of developing POI was significantly higher in those offered OTC (hazard ratio [HR] 8.7 [95% CI 3.6\u201321]; P\u2009&lt;\u20090.0001), even when those patients with unknown outcomes were excluded from the analysis (HR 8.1 [95% CI 3.4\u201320]; P\u2009&lt;\u20090.001). All patients offered OTC who developed POI did so after treatment for primary disease; in those not offered OTC, five patients (45.5%) developed POI after treatment for disease relapse.<\/jats:p>\n <\/jats:sec>\n \n LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n A significant number of patients had unknown reproductive outcomes; many of these patients were engaged in ongoing follow-up but did not have documented reproductive assessment. This may have introduced bias to the analysis and highlights the need for reproductive follow-up as part of routine cancer aftercare. In addition, the relatively young age of the patient population and short duration of follow-up in some cases demonstrates the need for ongoing follow-up of this cohort.<\/jats:p>\n <\/jats:sec>\n \n WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n The prevalence of POI after childhood cancer is low, but the Edinburgh selection criteria remain a robust tool for selecting those at high risk at the time of diagnosis, to offer OTC appropriately. However, disease relapse necessitating more intensive treatments remains a challenge. This study additionally highlights the importance of routine assessment and documentation of reproductive status in haematology\/oncology follow-up.<\/jats:p>\n <\/jats:sec>\n \n STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n K.D. is supported by a CRUK grant (C157\/A25193). This work was undertaken in part in the MRC Centre for Reproductive Health, (supported by MRC grant MR\/N022556\/1). R.A.A. has received consulting fees from Ferring and Roche Diagnostics; payment from Merck and IBSA for educational events; and laboratory materials from Roche Diagnostics. The other authors have no competing interests to declare.<\/jats:p>\n <\/jats:sec>\n \n TRIAL REGISTRATION NUMBER<\/jats:title>\n N\/A.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/humrep\/dead060","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T22:41:46Z","timestamp":1680561706000},"page":"1076-1085","source":"Crossref","is-referenced-by-count":19,"title":["Long-term follow-up to assess criteria for ovarian tissue cryopreservation for fertility preservation in young women and girls with cancer"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0039-8525","authenticated-orcid":false,"given":"Kathleen","family":"Duffin","sequence":"first","affiliation":[{"name":"Biomedical Sciences, University of Edinburgh , Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4380-969X","authenticated-orcid":false,"given":"Ruth","family":"Howie","sequence":"additional","affiliation":[{"name":"Edinburgh Fertility Centre, Simpsons Centre for Reproductive Health, Royal Infirmary of Edinburgh , Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8091-1458","authenticated-orcid":false,"given":"Tom W","family":"Kelsey","sequence":"additional","affiliation":[{"name":"Department of Computer Science, University of St Andrews , St Andrews, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-5674","authenticated-orcid":false,"given":"Hamish B","family":"Wallace","sequence":"additional","affiliation":[{"name":"Department of Child Life and Health, University of Edinburgh , Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7495-518X","authenticated-orcid":false,"given":"Richard A","family":"Anderson","sequence":"additional","affiliation":[{"name":"MRC Centre for Reproductive Health, Queens Medical Research Institute, University of Edinburgh , Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"key":"2023060106273397600_dead060-B1","first-page":"1","article-title":"ESHRE guideline: female fertility preservation","volume":"2020","author":"Anderson","year":"2020","journal-title":"Hum Reprod Open"},{"key":"2023060106273397600_dead060-B2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ejca.2020.11.032","article-title":"Cancer survivorship: reproductive health outcomes should be included in standard toxicity assessments","volume":"144","author":"Anderson","year":"2021","journal-title":"Eur J Cancer"},{"key":"2023060106273397600_dead060-B3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/humrep\/det388","article-title":"The immature human ovary shows loss of abnormal follicles and increasing follicle developmental competence through childhood and adolescence","volume":"29","author":"Anderson","year":"2014","journal-title":"Hum Reprod"},{"key":"2023060106273397600_dead060-B4","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1530\/REP-08-0097","article-title":"Ovarian cryopreservation for fertility preservation: indications and outcomes","volume":"136","author":"Anderson","year":"2008","journal-title":"Reproduction"},{"key":"2023060106273397600_dead060-B5","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S1470-2045(15)70140-3","article-title":"Parenthood in adult female survivors treated for Hodgkin\u2019s lymphoma during childhood and adolescence: a prospective, longitudinal study","volume":"16","author":"Br\u00e4mswig","year":"2015","journal-title":"Lancet Oncol"},{"key":"2023060106273397600_dead060-B6","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1210\/jc.2006-0020","article-title":"Acute ovarian failure in the childhood cancer survivor study","volume":"91","author":"Chemaitilly","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2023060106273397600_dead060-B7","author":"Children with Cancer UK","year":"2021"},{"key":"2023060106273397600_dead060-B8","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S1470-2045(16)00086-3","article-title":"Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort","volume":"17","author":"Chow","year":"2016","journal-title":"Lancet Oncol"},{"key":"2023060106273397600_dead060-B9","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/humrep\/dev128","article-title":"Live birth after autograft of ovarian tissue cryopreserved during childhood","volume":"30","author":"Demeestere","year":"2015","journal-title":"Hum Reprod"},{"key":"2023060106273397600_dead060-B10","first-page":"436","article-title":"Risk of transplanting malignant cells in cryopreserved ovarian tissue","volume":"70","author":"Dolmans","year":"2018","journal-title":"Minerva Ginecol"},{"key":"2023060106273397600_dead060-B11","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(04)17222-X","article-title":"Livebirth after orthotopic transplantation of cryopreserved ovarian tissue","volume":"364","author":"Dolmans","year":"2004","journal-title":"Lancet"},{"key":"2023060106273397600_dead060-B12","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.fertnstert.2021.03.008","article-title":"Transplantation of cryopreserved ovarian tissue in a series of 285 women: a review of five leading European centers","volume":"115","author":"Dolmans","year":"2021","journal-title":"Fertil Steril"},{"key":"2023060106273397600_dead060-B13","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1126\/science.aav7321","article-title":"Chromosome errors in human eggs shape natural fertility over reproductive life span","volume":"365","author":"Gruhn","year":"2019","journal-title":"Science"},{"key":"2023060106273397600_dead060-B14","author":"Harrison","year":"2020"},{"key":"2023060106273397600_dead060-B15","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/humrep\/dex040","article-title":"Efficacy of ovarian tissue cryopreservation for fertility preservation: lessons learned from 545 cases","volume":"32","author":"Jadoul","year":"2017","journal-title":"Hum Reprod"},{"key":"2023060106273397600_dead060-B16","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00383-019-04503-3","article-title":"Development of a new reproductive tissue cryopreservation clinical service for children: the Oxford programme","volume":"35","author":"Lakhoo","year":"2019","journal-title":"Pediatr Surg Int"},{"key":"2023060106273397600_dead060-B17","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.annonc.2020.09.006","article-title":"Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines","volume":"31","author":"Lambertini","year":"2020","journal-title":"Ann Oncol"},{"key":"2023060106273397600_dead060-B18","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1093\/humrep\/dex297","article-title":"Fertility-related knowledge and reproductive goals in childhood cancer survivors: short communication","volume":"32","author":"Lehmann","year":"2017","journal-title":"Hum Reprod"},{"key":"2023060106273397600_dead060-B19","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/cncr.31121","article-title":"Nonsurgical premature menopause and reproductive implications in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study","volume":"124","author":"Levine","year":"2018","journal-title":"Cancer"},{"key":"2023060106273397600_dead060-B20","doi-asserted-by":"crossref","first-page":"1179558119867357","DOI":"10.1177\/1179558119867357","article-title":"Ovarian tissue transplantation: experience from Germany and worldwide efficacy","volume":"13","author":"Lotz","year":"2019","journal-title":"Clin Med Insights Reprod Health"},{"key":"2023060106273397600_dead060-B21","first-page":"432","article-title":"Successful pregnancy in a woman previously suffering from beta-thalassaemia following transplantation of ovarian tissue cryopreserved before puberty","volume":"70","author":"Matthews","year":"2018","journal-title":"Minerva Ginecol"},{"key":"2023060106273397600_dead060-B22","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S1470-2045(20)30594-5","article-title":"Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"22","author":"Mulder","year":"2021","journal-title":"Lancet Oncol"},{"key":"2023060106273397600_dead060-B23","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","article-title":"Fertility preservation in patients with cancer: ASCO clinical practice guideline update","volume":"36","author":"Oktay","year":"2018","journal-title":"J Clin Oncol"},{"key":"2023060106273397600_dead060-B24","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.fertnstert.2019.09.013","article-title":"Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion","volume":"112","author":"Practice Committee of the American Society for Reproductive Medicine","year":"2019","journal-title":"Fertil Steril"},{"key":"2023060106273397600_dead060-B25","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2021"},{"key":"2023060106273397600_dead060-B26","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.3324\/haematol.2021.278828","article-title":"Successful pregnancies after transplantation of ovarian tissue retrieved and cryopreserved at time of childhood acute lymphoblastic leukemia\u2014a case report","volume":"106","author":"Rodriguez-Wallberg","year":"2021","journal-title":"Haematologica"},{"key":"2023060106273397600_dead060-B27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10815-012-9912-x","article-title":"The safety of transplanting cryopreserved ovarian tissue in cancer patients: a review of the literature","volume":"30","author":"Rosendahl","year":"2013","journal-title":"J Assist Reprod Genet"},{"key":"2023060106273397600_dead060-B28","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/09513590.2018.1488957","article-title":"Chinese Society of Gynecological Endocrinology affiliated to the International Society of Gynecological Endocrinology Guideline for Ovarian Tissue Cryopreservation and Transplantation","volume":"34","author":"Ruan","year":"2018","journal-title":"Gynecol Endocrinol"},{"key":"2023060106273397600_dead060-B29","author":"Scottish Intercollegiate Guidelines Network (SIGN)","year":"2013"},{"key":"2023060106273397600_dead060-B30","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1093\/humrep\/deaa175","article-title":"Live births following fertility preservation using in-vitro maturation of ovarian tissue oocytes","volume":"35","author":"Segers","year":"2020","journal-title":"Hum Reprod"},{"key":"2023060106273397600_dead060-B31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.fertnstert.2017.09.001","article-title":"First delivery in a leukemia survivor after transplantation of cryopreserved ovarian tissue, evaluated for leukemia cells contamination","volume":"109","author":"Shapira","year":"2018","journal-title":"Fertil Steril"},{"key":"2023060106273397600_dead060-B32","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0140-6736(10)60752-0","article-title":"Stillbirth and neonatal death in relation to radiation exposure before conception: a retrospective cohort study","volume":"376","author":"Signorello","year":"2010","journal-title":"Lancet"},{"key":"2023060106273397600_dead060-B33","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.rbmo.2021.10.009","article-title":"Cryopreservation of paediatric ovarian tissue with an updated version of the Edinburgh criteria for appropriate patient selection","volume":"44","author":"Takae","year":"2022","journal-title":"Reprod Biomed Online"},{"key":"2023060106273397600_dead060-B34","author":"Therneau","year":"2021"},{"key":"2023060106273397600_dead060-B35","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2000"},{"key":"2023060106273397600_dead060-B36","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/humrep\/des391","article-title":"Age at menopause and its influencing factors in a cohort of survivors of childhood cancer: earlier but rarely premature","volume":"28","author":"Thomas-Teinturier","year":"2013","journal-title":"Hum Reprod"},{"key":"2023060106273397600_dead060-B37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202805","article-title":"Perinatal risks in female cancer survivors: a population-based analysis","volume":"13","author":"Van Der Kooi","year":"2018","journal-title":"PLoS One"},{"key":"2023060106273397600_dead060-B38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1470-2045(05)70092-9","article-title":"Fertility preservation for young patients with cancer: who is at risk and what can be offered?","volume":"6","author":"Wallace","year":"2005","journal-title":"Lancet Oncol"},{"key":"2023060106273397600_dead060-B39","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1470-2045(14)70334-1","article-title":"Fertility preservation for girls and young women with cancer: population-based validation of criteria for ovarian tissue cryopreservation","volume":"15","author":"Wallace","year":"2014","journal-title":"Lancet Oncol"},{"key":"2023060106273397600_dead060-B40","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/humrep\/dew027","article-title":"ESHRE guideline: management of women with premature ovarian insufficiency","volume":"31","author":"Webber","year":"2016","journal-title":"Hum Reprod"},{"key":"2023060106273397600_dead060-B41","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Softw"},{"key":"2023060106273397600_dead060-B42","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/cncr.31862","article-title":"Fertility counseling before cancer treatment and subsequent reproductive concerns among female adolescent and young adult cancer survivors","volume":"125","author":"Young","year":"2019","journal-title":"Cancer"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/38\/6\/1076\/50489178\/dead060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/38\/6\/1076\/50489178\/dead060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T06:40:13Z","timestamp":1685601613000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/38\/6\/1076\/7100840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,3]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,4,3]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/dead060","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2023,4,3]]}}}